TD001 is a novel antibody-drug conjugate (ADC) designed to treat metastatic castration-resistant prostate cancer (mCRPC).
It targets prostate-specific membrane antigen (PSMA) and delivers the chemotherapeutic agent exatecan to induce DNA damage and cell death. Preclinical studies in animal models showed that TD001 effectively targeted tumors even with varying levels of PSMA expression, suggesting potential flexibility compared to other treatments (Read Pluvicto, which requires high levels of PSMA).
The ADC demonstrated high tumor uptake and a very high tumor/plasma ratio of exatecan across different models. TD001 is scheduled for presentation at AACR 2025.
